International Psoriasis Council

Advancing Knowledge. Improving Care.

Corporate Members

WORKING COLLECTIVELY TO ADVANCE PSORIASIS RESEARCH AND PATIENT CARE

As a network of the leading experts in psoriasis, we convene, collaborate, and partner with all stakeholders to exchange knowledge and influence how patients are treated worldwide. Below are our current corporate members who support and collaborate on our work.

DIAMOND MEMBERS

The AbbVie logo, designed for IPC partners, features the company name in lowercase, modern black lettering on a white background.
The image displays the Johnson & Johnson logo in bold red text on a white background, highlighting the words Johnson & Johnson in a distinctive serif font, symbolizing trust and collaboration with IPC partners.
The logo of Eli Lilly and Company, featured by IPC partners, displays the word Lilly in an elegant red cursive script on a white background.
The image shows the Takeda logo, featuring the word Takeda in red, italicized font inside a red curved arch with pointed ends on a white background, representing its association with IPC partners.

PLATINUM MEMBERS

The image shows the Novartis logo, featuring a stylized flame-like symbol in orange, red, and blue, followed by the word NOVARTIS in bold blue uppercase letters, highlighting its association with IPC partners.

GOLD MEMBERS

A line drawing of a lion with a detailed mane, standing on all four legs and facing right, with the word LEO in bold capital letters below the illustration, symbolizes the strength and unity of IPC partners.
Blue and white UCB logo next to the slogan: Inspired by patients. Driven by science. on a white background, highlighting collaboration with IPC partners.

SILVER MEMBERS

Logos of two pharmaceutical companies and IPC partners: on the left, the Almirall logo with a turquoise icon and navy text; on the right, the Sun Pharma logo with an orange circular icon and black text.
The image shows the AMGEN logo, with the company name AMGEN in bold, blue, uppercase letters on a white background, highlighting its collaboration with IPC partners.

BRONZE MEMBERS

Alumis logo featuring three overlapping, rounded shapes in red and pink forming a triangle next to the word alumis in bold black lowercase letters on a white background, highlighting its connection with IPC partners.
Logo for Arcutis Biotherapeutics, in collaboration with IPC partners, featuring the company name in gray and yellow text, plus three gray circles and a yellow curved line forming an abstract design above "arCUTIS.
Logo for Oruka Therapeutics, created for IPC partners, featuring a circular design with wave and sail shapes in blue tones, placed to the left of the company name in bold blue text.

Support Our Work

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026